American Journal of Cardiology Study Finds TAXUS Has Lower MACE Rate Than Cypher
Natick, Massachusetts, Aug. 16 -- Boston Scientific Corporation
today welcomed the results of an independent study demonstrating that Boston
Scientific's TAXUS® Express2™ paclitaxel- eluting stent system
had lower incidents of major adverse cardiac events (MACE) than Johnson & Johnson's
Cypher® sirolimus-eluting stent system. The results of the study were published
in the August 1 edition of the American Journal of Cardiology.
The study showed a safety trend in favor of TAXUS over Cypher in the cumulative one-year MACE rate, the study's primary endpoint, which was 15.6 percent for TAXUS versus 20.4 percent for Cypher. Of the three MACE components, the results favored TAXUS over Cypher in the cumulative rates of target vessel revascularization (TVR, or retreatment rate) (5.9 percent for TAXUS versus 10.3 percent for Cypher) and myocardial infarction (10 percent for TAXUS versus 14.1 percent for Cypher). For the third MACE component, cumulative mortality, the results were essentially equivalent (7.2 percent for TAXUS versus 7.7 percent for Cypher).
"The major finding of this study is that unrestricted use of PESs [paclitaxel-eluting stents] in a universal drug-eluting stent environment is associated with a nonsignificantly lower incidence of major adverse cardiac events at one year compared with SESs [sirolimus-eluting stents]," according to the study.
"We are pleased that this new study reconfirms the strong safety profile of paclitaxel-eluting stent systems we have seen across our broad range of clinical trials as well as in approximately 1.5 million TAXUS systems implanted to date," said Hank Kucheman, President of Boston Scientific's Interventional Cardiology business. "It is particularly impressive that the safety results demonstrated a trend in favor of the paclitaxel-eluting system among the challenging diabetic patient population in this study. Our focus on safety is one of the reasons TAXUS is the worldwide market leader in drug- eluting stents."
The study, conducted at the Rotterdam Cardiology Hospital in The Netherlands, included 293 patients with diabetes and de novo coronary artery disease who were enrolled in identical sequential registries, one assessing the paclitaxel-eluting stents and one assessing the sirolimus-eluting stents.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.
This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with clinical trials, the regulatory approval process, commercialization of new technologies, intellectual property, and other factors described in the Company's filings with the Securities and Exchange Commission.
CONTACT:
Milan Kofol
508-650-8569
Investor Relations
Boston Scientific Corporation
Paul Donovan
508-650-8541
Media Relations
Boston Scientific Corporation
Source: Boston Scientific Corporation
|
